WO2005009473A1 - 抗真菌エアゾール外用製剤 - Google Patents
抗真菌エアゾール外用製剤 Download PDFInfo
- Publication number
- WO2005009473A1 WO2005009473A1 PCT/JP2004/010466 JP2004010466W WO2005009473A1 WO 2005009473 A1 WO2005009473 A1 WO 2005009473A1 JP 2004010466 W JP2004010466 W JP 2004010466W WO 2005009473 A1 WO2005009473 A1 WO 2005009473A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aerosol
- antifungal
- external
- present
- water
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Definitions
- the present invention relates to an external aerosol preparation containing an antifungal component as an active ingredient.
- Antifungal agents are medicaments for preventing or treating fungal infectious diseases such as athlete's foot, candidiasis, and beetles.
- butenafine hydrochloride is a benzylamine-type antifungal agent.
- An antifungal compound such as butenafine hydrochloride, which has been conventionally used as an external preparation in the form of a solution, cream, etc., is used in an aluminum aerosol can.
- the metal surface of the aerosol can is reduced by hydrogen ions generated when the compound dissolves, and the metal equivalent to the hydrogen ions is ionized.
- Patent Document 1 discloses a means for improving the skin permeability of butenafine hydrochloride and preventing the metal corrosion from the pinhole portion by using a liquid formulation with a minimum water content. ing. In many cases, it is desirable to contain water from the viewpoint of keratin permeability, etc.In such a case, in such a case, the above-described method can prevent corrosion of the aerosol can while ensuring sufficient keratin permeability. It is difficult to prevent.
- the water content of the aerosol external preparation enhances the cooling sensation at the time of application and enhances its persistence, so that itching in patients with itching can be alleviated. Since it is the least irritating ingredient, it has the advantage of higher safety compared to preparations containing a large amount of alcohol.
- Patent Document 1 JP 2001-181182 A
- an object of the present invention is to provide an external aerosol preparation that improves skin penetration of antifungal components and does not lead to corrosion of aerosol cans.
- an external aerosol preparation comprises a stock solution comprising an antifungal component, water and a lipophilic surfactant of HLB1-9, and an alcohol solution. It has been found that the above objects can be achieved by containing the compound, and the present invention has been completed.
- the present invention relates to an external aerosol preparation containing a stock solution comprising an antifungal component, water and a lipophilic surfactant of HLB1-9.
- the present invention relates to the above external aerosol preparation, wherein the antifungal component is butenafine hydrochloride.
- the present invention relates to the aerosol external preparation, further comprising an alcohol.
- the present invention relates to the aforementioned external preparation for aerosol, which is alcoholic power and ethanol.
- the present invention relates to the aerosol external preparation, wherein the stock solution is a W / O liquid.
- the present invention relates to an antifungal aerosol product for external use, which comprises the aerosol external preparation.
- the mechanism of action of the external aerosol preparation of the present invention is not necessarily clear, but by using water and a surfactant in a stock solution containing an antifungal component, the outer layer is oil and the inner layer is water. Even if the antifungal component and water coexist, the hydrogen ions generated by the dissolution of the antifungal component in water do not come into contact with the metal surface of the aerosol can, so the aerosol can does not corrode. it is conceivable that.
- an active ingredient which is liable to cause metal corrosion such as butenafine hydrochloride
- the external preparation for aerosol of the present invention can contain water, it enhances the cooling sensation at the time of application or after application, thereby improving the antipruritic property or the irritation to the skin. Overall physical properties can be improved, such as reduction in safety.
- the antifungal component can contain a sufficient amount of water to improve skin permeability and the like, and does not lead to corrosion of the inner surface of the aerosol container.
- An external aerosol formulation useful for preventing or treating fungal infections can be obtained.
- the antifungal component used in the present invention is not particularly limited as long as it has an antifungal activity, but examples thereof include miconazole nitrate, econazole nitrate, terbinafine hydrochloride, butenafine hydrochloride, and neticonazole hydrochloride. Specifically, it is butenafine hydrochloride or neticonazole hydrochloride.
- the lipophilic surfactant of HLB1-9 of the present invention is not particularly limited, but preferred examples thereof include glycerin fatty acid esters such as propylene glycol monostearate, glyceryl monostearate and glyceryl monooleate.
- glycerin fatty acid esters such as diglyceryl monooleate, diglyceryl monoisostearate, and hexaglylate tristearate; sorbitan fatty acid esters such as sorbitan monooleate and sorbitan monolaurate; sorbitan sesquioleate and sorbitan trioleate; and polyoxyethylene castor oil 3 And polyoxyethylene hydrogenated castor oil 5.
- the external preparation for aerosol of the present invention may be in any form as long as a desired anticorrosive effect can be obtained.
- the stock solution contained in the preparation is preferably a W / II type liquid.
- the alcohol used in the present invention is, for example, a lower alcohol such as methanol, ethanol, or isopropanol, and is preferably ethanol.
- butenafine hydrochloride when used, it is not particularly limited as long as the object of the present invention can be achieved, but the concentration of butenafine hydrochloride in the stock solution is 0.1 to 10.0 wt%, and the water concentration is 3.0 90wt%, alcohol concentration is 1.0-70wt%, The concentration of the surfactant is preferably 0.1 to 10% by weight.
- the pH value is adjusted to a high level
- the pH is preferably in the range of 3 to 8 in consideration of crystal precipitation due to reduced solubility of the antifungal component.
- propellant for the aerosol preparation of the present invention a known propellant can be used.
- dimethyl ether dimethyl ether, liquefied petroleum gas, CFCs, N, CO gas,
- the aluminum can is commonly used, that is, an aluminum can coated with an epoxy resin, a phenol resin, a polyamideimide resin, or the like.
- the antifungal external aerosol product used in the present invention is an aerosol can containing an aerosol external preparation.
- the aerosol external preparation of the present invention can appropriately contain other pharmaceutically acceptable ingredients such as an antioxidant, a pH adjuster, a preservative, a preservative, and a fragrance, depending on the use.
- Solution A Dissolve butenafine hydrochloride lg in 40 g of ethanol, add 4 g of diglyceryl monoisostearate and 5 g of isopropyl myristate, and stir.
- Solution B Add 45 g of water and 5 g of 1,3-butylene glycol and stir.
- Example 1 was stored at 40 ° C for 6 months, the inner surface of the can was examined, and no pitting was observed.
- Solution A Butenafine hydrochloride lg, menthol 2 g, diburic acid hydrochloride 0.2 g, chlorphenylamine maleate 0.5 g, glycyrrhetinic acid 0.2 g, dibutylhydroxytoluene 0.lg Dissolve in lOg, add 4g of glycerin monooleate and 2g of otatildodecyl myristate and stir.
- Solution B 75 g of water and 5 g of 1,3-butylene glycol are added and stirred.
- Example 2 After storing Example 2 at 40 ° C. for 6 months, the inner surface of the can was examined. As a result, no pitting corrosion was observed.
- Example 3 After storing Example 3 at 40 ° C. for 6 months, the inner surface of the can was examined. As a result, no pitting was observed.
- Solution A 3 g of butenafine hydrochloride, menthol lg, 0.5 g of dibuforce hydrochloride, 0.5 g of chlorpheniramine maleate in 30 g of ethanol, 2 g of diglyceryl monoisostearate and 3 g of diisopropyl adipate are stirred. .
- Solution B 55 g of water and 5 g of glycerin are added and stirred.
- Example 4 After storing Example 4 at 40 ° C. for 6 months, the inner surface of the can was examined. As a result, no pitting corrosion was observed.
- Comparative Example 1 After storing Comparative Example 1 at 40 ° C. for 6 months, the inner surface of the can was examined. As a result, pitting was observed on the aerosol can and the contents leaked.
- the antifungal component can contain water, and the inside of the aerosol container such as an aluminum can is not corroded, and good preparation stability is obtained. It becomes possible.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003280287A JP4615198B2 (ja) | 2003-07-25 | 2003-07-25 | 抗真菌エアゾール外用製剤 |
JP2003-280287 | 2003-07-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005009473A1 true WO2005009473A1 (ja) | 2005-02-03 |
Family
ID=34100858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/010466 WO2005009473A1 (ja) | 2003-07-25 | 2004-07-23 | 抗真菌エアゾール外用製剤 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP4615198B2 (ja) |
TW (1) | TW200503776A (ja) |
WO (1) | WO2005009473A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2057988B1 (en) * | 2006-08-28 | 2013-09-11 | Hisamitsu Pharmaceutical Co., Inc. | Nail patch |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990011068A1 (fr) * | 1989-03-17 | 1990-10-04 | Taisho Pharmaceutical Co., Ltd. | Preparation aerosol a usage externe |
JPH04103526A (ja) * | 1990-08-21 | 1992-04-06 | Taisho Pharmaceut Co Ltd | 皮膚冷却エアゾール剤 |
JPH11335265A (ja) * | 1998-05-20 | 1999-12-07 | Taisho Pharmaceut Co Ltd | 皮膚外用剤 |
WO2000023051A1 (en) * | 1998-10-19 | 2000-04-27 | Oms Holdings, Llc | Aerosol ointment compositions and method of manufacture |
JP2001181182A (ja) * | 1999-12-22 | 2001-07-03 | Takeda Chem Ind Ltd | 抗真菌性液体外用組成物 |
JP2002524490A (ja) * | 1998-09-11 | 2002-08-06 | ソルテック リサーチ プロプライアタリィ リミティド | ムースの組成 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA96514B (en) * | 1995-01-27 | 1996-08-13 | Johnson & Son Inc S C | Insecticidally-active composition |
JP4394775B2 (ja) * | 1999-09-03 | 2010-01-06 | 株式会社ダイゾー | 油中水型泡状エアゾール組成物およびその製造方法 |
JP4394779B2 (ja) * | 1999-10-01 | 2010-01-06 | 株式会社ダイゾー | 油中水型エアゾール組成物およびその製造方法 |
JP2002292270A (ja) * | 2001-03-30 | 2002-10-08 | Sunstar Inc | 多相エマルジョン |
JP2002309241A (ja) * | 2001-04-13 | 2002-10-23 | Daizo:Kk | 油中水型エアゾール製品 |
-
2003
- 2003-07-25 JP JP2003280287A patent/JP4615198B2/ja not_active Expired - Lifetime
-
2004
- 2004-07-23 TW TW093122087A patent/TW200503776A/zh unknown
- 2004-07-23 WO PCT/JP2004/010466 patent/WO2005009473A1/ja active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990011068A1 (fr) * | 1989-03-17 | 1990-10-04 | Taisho Pharmaceutical Co., Ltd. | Preparation aerosol a usage externe |
JPH04103526A (ja) * | 1990-08-21 | 1992-04-06 | Taisho Pharmaceut Co Ltd | 皮膚冷却エアゾール剤 |
JPH11335265A (ja) * | 1998-05-20 | 1999-12-07 | Taisho Pharmaceut Co Ltd | 皮膚外用剤 |
JP2002524490A (ja) * | 1998-09-11 | 2002-08-06 | ソルテック リサーチ プロプライアタリィ リミティド | ムースの組成 |
WO2000023051A1 (en) * | 1998-10-19 | 2000-04-27 | Oms Holdings, Llc | Aerosol ointment compositions and method of manufacture |
JP2001181182A (ja) * | 1999-12-22 | 2001-07-03 | Takeda Chem Ind Ltd | 抗真菌性液体外用組成物 |
Non-Patent Citations (1)
Title |
---|
TOKIYUKI YOSHIDA ET AL.: "Shinhan Kaimen Kaisseizai Handbook", 20 May 2000 (2000-05-20), pages 237 - 238, XP002987040 * |
Also Published As
Publication number | Publication date |
---|---|
JP2005041850A (ja) | 2005-02-17 |
JP4615198B2 (ja) | 2011-01-19 |
TW200503776A (en) | 2005-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11433025B2 (en) | Oil foamable carriers and formulations | |
EP2395839B1 (en) | Anti-fungal formulation | |
US9884017B2 (en) | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof | |
US20070292355A1 (en) | Anti-infection augmentation foamable compositions and kit and uses thereof | |
JP2003012511A (ja) | エアゾール組成物 | |
JP2002284702A (ja) | 外用抗真菌製剤 | |
AU2007355106A1 (en) | Foamable waterless compositions with modulating agents | |
WO2005000287A1 (ja) | 水虫治療用外用剤 | |
US8802653B2 (en) | Deodorant compositions | |
JP4431369B2 (ja) | 抗真菌エアゾール外用製剤 | |
JP4856868B2 (ja) | エアゾール組成物 | |
WO2005009473A1 (ja) | 抗真菌エアゾール外用製剤 | |
JP2005170913A (ja) | 抗真菌性外用組成物 | |
JP2000229845A (ja) | 抗真菌剤含有粉末エアゾール製剤 | |
EP2353579B1 (en) | Deodorant composition | |
JP3533228B2 (ja) | 低刺激性ニトログリセリン組成物及びスプレー剤 | |
US20230172814A1 (en) | Lidocaine solution and foot wipe | |
JP4559753B2 (ja) | 皮膚外用クリーム剤 | |
JP4293883B2 (ja) | デオドラント組成物 | |
JP2017071574A (ja) | エタノール含有エアゾール製剤 | |
JP4298973B2 (ja) | 非水系エアゾール剤 | |
WO2005032532A1 (ja) | 抗真菌組成物 | |
JP2002167328A (ja) | 皮膚外用組成物および皮膚外用エアゾール組成物 | |
JPH09110677A (ja) | エアゾール剤 | |
JPH04149131A (ja) | インドメタシン外用液剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |